

## 7. An international collaboration to conduct large-scale trials of nonpharmacological interventions in scleroderma: the Scleroderma Patient-centered Intervention Network (SPIN).

**Linda Kwakkenbos**<sup>1,2</sup>, Lisa R. Jewett, MSc <sup>2,3</sup>; Brett D. Thombs, PhD <sup>1,2,3</sup>, and the SPIN investigators.

<sup>1</sup>Department of Psychiatry, McGill University, Montréal, Québec, Canada; <sup>2</sup>Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada; <sup>3</sup>Department Educational and Counselling Psychology, McGill University, Montréal, Québec, Canada

**Background:** Psychosocial and rehabilitation interventions are increasingly used to attenuate disability and improve health-related quality of life (HRQL) in chronic diseases, but are typically not available for patients with rare diseases such as scleroderma (systemic sclerosis, SSc). Conducting rigorous, adequately-powered trials of these interventions for patients with rare diseases is difficult. The Scleroderma Patient-centered Intervention Network (SPIN) is an international collaboration of patient organizations, clinicians, and researchers. The aim of SPIN is to develop a research infrastructure to test accessible, low-cost self-guided online interventions to reduce disability and improve HRQL for people living with scleroderma. Once tested, effective interventions will be made accessible through patient organizations partnering with SPIN.

Methods: SPIN will utilize a novel research design, the cohort multiple RCT (cmRCT) design to collect longitudinal data related to problems experienced by people living with SSc and as a framework for developing, evaluating, and delivering psychosocial and rehabilitation interventions. In the cmRCT design, patients consent to participate in a cohort for ongoing data collection. The aim is to recruit 1,500-2,000 patients from centers across the world within a period of 5 years (2013-2018). Eligible participants are persons ≥18 years of age with a diagnosis of systemic sclerosis. In addition to baseline medical data, participants will complete patient-reported outcome measures every 3 months. Upon enrolment in the cohort, patients will consent to be contacted in the future to participate in interventions tested with other cohort participants. Once interventions are developed, patients from the cohort will be randomly selected and offered interventions as part of pragmatic RCTs. Outcomes from patients offered interventions will be compared to outcomes from trial-eligible patients who are not offered the interventions.

**Discussion:** The use of the cmRCT design, the development of self-guided online interventions, and partnerships with patient organizations will allow SPIN to develop, rigorously test, and effectively disseminate psychosocial and rehabilitation interventions for people with scleroderma.